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Evidence and ecacy
(Allergen-)Specic immunotherapy (AIT) is cur-
rently the only treatment available that is capable of 
inducing specic tolerance to individual allergens, 
particularly in allergies to inhalant allergens [1]. In 
principle, due to its disease-modifying eects that 
may manifest as asthma prevention and the preven-
tion of new sensitizations, AIT is superior to purely 
symptomatic treatment [2, 3]. However, studies 
have proven these eects for only a scant number of 
products. A variety of preparations are available for 
subcutaneous and sublingual use, whereby native 
or chemically modied allergens (allergoids) can be 
used. e practitioner needs to establish which 
product should be used, taking into consideration 
ecacy, safety, time expenditure for the patient, as 
wells as costs.
e revised S2k-guideline [4] published at the end 
of 2014 is based on the current state of knowledge 
and provides physicians with excellent support 
when deciding for or against AIT, as well as in the 
selection of allergen preparations. One of the guide-
line‘s core statements is a call to evaluate each indi-
vidual preparation on the basis of the study results 
available for that preparation, irrespective of its 
mode of administration. In the opinion of the 
 authors, approved allergen preparations with doc-
umented ecacy and safety, or preparations mar-
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Abstract
e recently published S2k-guideline on (allergen-) 
specic immunotherapy (AIT) provides an excel-
lent overview of the evidence on allergen prepara-
tions available for AIT in Germany based on the 
published ecacy studies. Publications based on 
the guideline are currently being used by the Ger-
man associations of statutory health insurance 
physicians and German health insurance funds to 
open a discussion on the reimbursement status of 
allergen preparations. In our view, calling the re-
imbursement status of perscribable and tradable 
AIT preparations into question on the basis of an 
assessment of the current body of evidence in the 
guideline is to be rigidly opposed. In Germany the 
Paul Ehrlich Institute (PEI) is the only authority 
empowered to decide on the marketability of AIT 
preparations, and decisions on the reimbursement 
status of AIT products need to be based on cost–
benet analyses and not solely on an evaluation of 
the evidence. e present article aims to examine 
the relationship between the evidence, ecacy, 
tradability, and reimbursability of AIT prepara-
tions.
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ketable under the erapy Allergen Ordinance 
(TAO) for which ecacy and safety have already 
been documented in clinical trials meeting World 
Allergy Organization (WAO) or European Medi-
cines Agency (EMA) standards, „should be prefer-
entially used“ [4].
AIT products are essentially challenging to com-
pare due to their heterogeneous composition. To 
date, the characterization and standardization of 
 allergen extracts has been performed according to 
manufacturer-specic standards and, even when 
major allergen concentrations are given, these do 
not permit conclusions to be drawn on possible 
 ecacy, since methods for the analysis of major 
 allergens are not consistent, and most allergen ex-
tracts contain several major allergens. is has lead 
to the indispensable requirement (as with other 
drugs) for reliable studies to analyze each  individual 
AIT preparation for ecacy and safety. is pres-
ents the prescribing physician with the dilemma of 
needing to be familiar with, and capable of evaluat-
ing, the study data.
By way of support here, the guideline refers read-
ers to tables listing allergen preparations that fall 
under the German TOA. ese tables are not an in-
tegral part of the guideline. ey provide informa-
tion on the following:
— Current marketing authorization status of indi-
vidual products
— e number of full publications evidencing the 
ecacy of each individual preparation listed
— −An overview of trials that have been conducted 






e tables are updated bi-annually and brought in 
line with the current status. Only the results of clin-
ical trials that fulll conditions dened on the ba-
sis of WAO criteria are included in the list (www.
dgaki.de/leitlinien/s2k-leitlinie-sit/sit-produk-
te-studien-zulassung) [5].
e conditions to be fullled for the guideline are 
the following:
1. Standardized allergen extract with dose informa-
tion,
2. randomized, double-blind, placebo-controlled 
study design,
3. information relating to a combined symp-
tom-medication score and/or the two individual 
scores,
4. information relating to statistical analysis and 
statistically signicant results,
5.  a threshold in ecacy of 20 % above placebo.
e rst point represents a minimum requirement 
in terms of product characterization stipulated by 
the Paul Ehrlich Institute for the marketing autho-
rization of an AIT product. Requirements 2–4 em-
phasize the evidence documenting that the product 
is eective. e term evidence (see denition in 
Tab. 1) stems from the Latin „evidentia“ and is the 
colloquial term for “obviousness” meaning that 
something does not need to be questioned [6]. us, 
evidence does not assess the magnitude of ecacy, 
but concerns rather the reliability with which 
something is proven to be eective.
e ©h criterion species a minimum level of 
ecacy. is criterion is not relevant to the market-
ing authorization of an AIT product at the Paul 
 Ehrlich Institute. e requirement is based on the 
concept that specic immunotherapy that is far 
more costly than pharmacotherapy needs to 
demonstrate at least an ecacy comparable to that 
of (here in the sense of antihistamine and/or  topical 
corticosteroids treatment). However, it must be 
borne in mind that clinical studies to assess the 
 eect of specic immunotherapy or of pharmaco-
therapy are designed dierently, and that the pos-
sible disease-modifying eect of AIT is not taken 
into account in this comparison. According to pub-
lished studies, a 20 % improvement in the symptom 
and medication score (generally measured in the 
rst year following AIT initiation) results in a rel-
evant improvement in quality of life.
Abbreviations
AIT  (Allergen-)specic immunotherapy
AMG   Medicinal Products Act  
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When considering the various AIT studies, one 
should bear in mind that the resulting strength of 
treatment can be aected by a number of factors 
that, to a certain extent, cannot be inªuenced and 
which are independent of the investigated prepara-
tion:
— Symptom severity in the study population
— Extent of sensitization among subjects
— Degree of pollination during the study season 
— Denition of the endpoint
— Statistical analysis
A further crucial factor is whether the intent-to-
treat (ITT) or the per-protocol (PP) population (see 
denitions in Tab. 1) is analyzed. While eect sizes 
may be identical in the PP and ITT, they can also 
dier widely.
A harmonization of studies is sought on both an 
international and a national level. However, the ef-
cacy of dierent allergen products can only be 
compared if dierent products are directly used in 
the same study. At present, it appears highly  unlikely 
that head-to-head studies of this kind will be con-
ducted in the foreseeable future.
Evidence assesses the reliability with which an in-
tervention is shown to be eective and does not per-
mit conclusions to be drawn on the size of the inter-
vention‘s eect. us, a lack of evidence is not tan-
tamount to a lack of ecacy, and the intervention 
with the highest level of evidence is not necessarily 
the most eective. However, a basic requirement 
should be that ecacy is shown in controlled  studies 
for all preparations containing common allergens 
currently on the market (see below). e TAO de-
nes the trial requirements that need to be fullled 
for marketing authorization.
Marketing authorization
AIT preparations that were granted marketing autho-
rization by the relevant authorities before the TAO 
came into force [8] have proven their ecacy in stud-
ies that satised the marketing authorization require-
ments at that time. According to the TAO, these 
preparations are not required to be investigated in 
new studies fullling current standards; they remain 
permanently tradable. Although this fact may appear 
worthy of discussion, it is understandable given that 
marketing authorization of drugs cannot be with-
drawn simply because the requirements made of tri-
als to establish ecacy have changed. Since the trials 
conducted in the past partially failed to satisfy WAO 
requirements for inclusion in the guideline tables, the 
tables contain older authorized products in particu-
lar, for which no ecacy trials are available (since the 
published trials do not fulll current criteria). How-
ever, this lack of data does not imply that no trials 
 exist or even that these preparations are necessarily 
ineective. More importantly, this is in no way linked 
to the assertion that the marketing authorization of 
these preparations is questionable and that their pre-
scription represents grounds for recourse. us, the 
guideline does not release allergologists from their 
duty to assess trial data on the products they use on 
an individual basis.
AIT with rare allergens
All the above-mentioned considerations apply only 
to AIT using frequently occurring allergens that fall 
under the TAO (species from the Poaceae family, ex-
cluding Poa mays [grasses, excluding maize], Betu-
la sp. [species in the birch genus], Alnus sp. [species 
in the alder genus], Corylus sp. [species of the hazel 
genus], Dermatophagoides sp. [species in the house 
dust mite genus], bee venom, and wasp venom) [8]. 
Despite the TAO‘s entry into force, current legis-
lation continues to make provision for the option to 
prescribe individual formulations of all other thera-
py allergens not belonging to the above-mentioned 
group (for instance, weed pollen [e. g., ragweed, 
mugwort, plantain, etc.], mold [e. g., Alternaria, As-
pergillus, Cladosporium], storage mites, animal 
dander [e. g., cat]).
e legislature chose this path for good reason. 
e studies involving large patient numbers that 
would be needed for the approval of rarer allergens 
Tab. 1: Denitions
Term Definition
Efficacy Efficacy compared with placebo as the difference 
 between the placebo and verum group in terms of 
 defined efficacy parameters
Evidence Stems from „evidentia“; reliability of the evidence of 
 efficacy
Evidence-based medicine The requirement in medical treatment to make a  
patient-oriented decision, where possible, on the basis 
of  empirically proven efficacy




Data of patients in the verum or placebo group are 
 analyzed, irrespective of whether treatment was subse-
quently carried out according to protocol
Tradability Prerequisite for a drug to be sold and used
Reimbursability The Joint Federal Committee holds the authority to 
 decide on limiting or excluding the performance and 
prescription of services 
Finished medicinal products Finished medicinal products are medicinal products that 
are manufactured in advance and placed on the market 
in packaging intended for the consumer, or other medi-
cinal products intended for consumers, the preparation 
of which involves an industrial procedure, or which are 
commercially manufactured (except in pharmacies)
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are virtually impracticable due to the number of pa-
tients required. Nevertheless, patients with allergies 
to rare allergens are equally entitled to cause-ori-
ented treatment using AIT. Preparations produced 
and marketed according to § 21 paragraph 2, 1b of 
the Medicinal Products Act (Arzneimittelgesetz, 
AMG) of the Federal Republic of Germany  continue 
to be available to these patients as individual formu-
lations for AIT. e 14th amendment of the AMG 
of 2005 regulates the exemption of therapy  allergens 
produced for individual patients from licensing re-
quirements. Specic immunotherapeutic agents 
produced on the basis of a prescription formulation 
are explicitly exempted from the obligation to ob-
tain marketing authorization in § 21 paragraph 2, 
1b of the AMG: “A marketing authorisation (Zu-
lassung) shall not be required for medicinal pro-
ducts which ... are prepared on prescription for in-
dividual persons.” Here again, no grounds for re-
course are provided for.
Reimbursement status
ere has been a discussion in recent months on 
possible restrictions on the reimbursment of aller-
gen extracts used for AIT. One publication in par-
ticular [9], which virtually compiles a positive list 
of products for AIT, forms the basis for this discus-
sion. e publication categorizes allergen products 
into a pyramid according to “rst choice” to “last 
choice.” While the current tables in the guideline 
appendix have our full endorsement, we see a real 
hazard in terms of interpretation posed by the spe-
cic classication of products – conveyed as the per-
sonal recommendation of the publication‘s author 
by virtue of the pyramid structure – into “recom-
mended” and “not recommended”, which does not 
lie in the intention of the guideline. In our view, re-
presenting products in such a way bears the risk that 
healthcare actors could indirectly instrumentalize 
the guideline as a means to decide on the reimburs-
ability of preparations. e guideline, as well as the 
tables in the appendix explicitly state that the table 
is „not suited as a positive or negative list for deci-
sion-making on prescribability or reimbursability.“ 
It is our opinion that deriving a positive list based 
on the guideline tables is also particularly unjusti-
ed since the issue does not relate to the actual e-
cacy of AIT products, but rather to merely present-
ing evidence according to criteria based on WAO 
recommendations. It is currently not possible to 
conduct an accurate, scientically founded compar-
ative assessment of the ecacy of the various AIT 
products, meaning that the prescriber of these pro-
ducts must not be limited in his therapeutic free-
dom via the loophole of decisions on  reimbursability. 
However, for patients’ well-being, any prescription 
of an AIT preparation should be based on ecacy 
data, and it is the responsibility of the prescribing 
physician to establish whether studies have proven 
the ecacy of the preparation that he/she wishes to 
prescribe.
Cost-benet analysis
Whereas the Paul Ehrlich Institute decides on the 
marketability of drugs, guidelines aimed at ensur-
ing medical care – as compiled by the Joint Federal 
Committe according to § 92 of the German Social 
Code (Sozialgesetzbuch, SGB) V – should enable the 
physician to make a cost-eective and appropriate 
selection of drug therapy. It has been specied that 
information shall be included that permits the phy-
sician to make an appropriate treatment and drug 
selection that is also based on treatment benet in 
relation to treatment costs, thereby serving the cost 
eectiveness of the prescription. According to § 35b 
SGB V, the Joint Committee tasks the German 
 Institute for Quality and Eciency in Health Care 
(Institut für Qualität und Wirtscha©lichkeit im 
 Gesundheitswesen, IQWIG) with drawing up a 
cost-benet analysis in which both the benet to the 
patient (disease improvement, reduced disease 
 duration, increased life expectancy, reduced side 
 eects, improved quality of life) and the economic 
analysis (appropriateness and reasonableness of 
 requesting the insured community to meets the 
costs) need to be taken into consideration. us, a 
well-founded selection of reimbursable or non-re-
imbursable products must be made on the basis of 
cost-benet analyses. A valid, preparation-specic 
calculation of the benet conferred by AIT is cur-
rently not possible since, in addition to reduced 
medication use and improved ability to work, as 
well as the long-term eects in terms of asthma 
 reduction and the prevention of new sensitizations, 
treatment with each individual preparation needs 
to be assessable.
Calculating the cost of AIT is also not unprob-
lematic. Due to varying treatment protocols, calcu-
lating dened daily doses (DDD) is not helpful and 
is considered obsolete today. Calculating costs over 
a dened period of time (the costs of treatment over 
a 3-year period are o©en used) is favored. However, 
it should be borne in mind here that the standard 
period for subcutaneous immunotherapy (SCIT) is 
currently 3 years, while a period of 3–5 years is in-
creasingly favored for preparations used in the con-
text of sublingual immunotherapy (SLIT). ere is 
a discussion as to whether a single treatment cycle 
of several weeks for peptide therapy may be adequate. 
erefore, rightfully speaking, the costs of a „com-
plete treatment cycle“ need to be assumed as a basis 
for calculating costs. 
Alternatively, comparative models in which the 
nancial expense of achieving a predened outcome 
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or quality-adjusted life years (QUALY) using dier-
ent treatments are under discussion. However, stud-
ies of this kind are still awaited for the individual 
allergen preparations.
Conclusion
e guideline provides an excellent overview of the 
AIT preparations used in Germany and, with its 
 tables, refers the reader to a current overview of the 
marketing approval status of these products, the 
published study results that fulll today‘s criteria 
(according to WAO), as well as the ocial approval 
to conduct AIT trials. Using the guideline to deduce 
the reimbursability of allergen products is to be 
 rigorously rejected. Reimbursability needs to be 
based on cost-benet calculations, which are cur-
rently not practicable in a preparation-specic man-
ner. e fact that it was not the intention of the 
guideline authors to inªuence the reimbursability 
of AIT products is clear from the wording in the 
 tables: „e tables are not suitable as a basis for 
 decision-making on prescribability or reimbursabil-
ity in the sense of a positive or negative list.“
Prof. Dr. Randolf Brehler
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A number of passages in the present article have been 
taken from a statement issued by the three specialist al-
lergology societies, AeDA, DGAKI, and GPA, and pub-
lished in Allergo Journal on the prescription forum No. 
34/2015 of the German association of statutory health in-
surance physicians (Baden-Württemberg) (Allergo J 2015, 
24(8);68–71 with kind permission of the Allergo Journal 
editorial board). As part of an agreement between the ed-
itorial boards of the respective journals, this paper will be 
published simultaneously in Allergo Journal and in Aller-
gologie, in order to reach the widest possible Ger-
man-speaking specialist readership in a timely manner.
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